Peer-influenced content. Sources you trust. No registration required. This is HCN.
OBR Oncology
Patients with newly diagnosed acute myeloid leukemia (AML) have had better results thanks to alterations to cytarabine/anthracycline-based intense chemotherapy, including the addition of high-dose cytarabine and adjustments to the dosage schedule or type of anthracycline.
Hematology January 23rd 2023
Blood
In conclusion, daratumumab (Darzalex) (D) was added to lenalidomide, bortezomib, and dexamethasone (RVd) in NDMM patients who were transplant-eligible, and this led to enhanced stringent complete response (sCR) and minimal residual disease (MRD)-negative rates, a tolerable safety profile, and no clinically meaningful effects on stem cell mobilization or engraftment. These findings suggest that the D-RVd combination may become a new standard of care for NDMM who are transplant-eligible.
Oakstone Publishing
Acquired/congenital bone marrow failure, thalassemia/hemoglobinopathies, transfusion medicine, new therapies (pharmacology), infections of the immunocompromised, hematologic malignancies (acute/chronic leukemias; myeloma/lymphomas), thoracic oncology (head/neck/lung/thyroid), and many other practice improvement areas are covered in this CME activity worth up to 41.25 credits. The video curriculum starts at $1,795 in price.
The New England Journal of Medicine
Overall survival was longer and the rate of remission was higher among patients who received azacitidine (Vidaza) with venetoclax (Venclexta) than among those who received azacitidine alone in previously untreated patients who were ineligible for intense chemotherapy. Compared to the control group, the venetoclax-azacitidine group had a greater incidence of febrile neutropenia.
Event-free survival (EFS) was significantly increased with enasidenib compared to conventional care regimens (CCR) in this open-label, randomized, phase 3 trial; overall survival (OS) was complicated by early dropout and usage of later AML medications. The older R/R mutant-IDH2 AML group received notable morphologic and hematologic responses from enasidenib as opposed to CCR.
Hematology January 17th 2023
MedPage Today
In terms of regulation, the PI3K inhibitor medication class had a difficult 2022. Participants in a historic FDA advisory committee meeting in April were warned about dubious safety and efficacy. Less than three months later, the FDA issued a duvelisib (Copiktra) safety warning about mortality rates. As a result, the FDA’s Oncologic Drugs Advisory Committee (ODAC) decided against recommending duvelisib’s approval for the treatment of chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL). Along the way, the FDA also voluntarily withdrew or revoked a number of PI3K inhibitors’ approved indications. Does the medication class have a promising future in the treatment of hematologic malignancies in light of this negative energy?
Hematology January 9th 2023